Russian Journal of Allergy最新文献

{"title":"New coronavirus infection SARS-CoV-2 in adult patients with inborn errors of immunity.","authors":"Anna Roppelt, Ulyana Mаrkina, E. Bobrikova, Tatiana Кruglova, Olga Мukhina, M. Lebedkina, G. Andrenova, Anton Chernov, Ekaterina Alexeeva, Alexander Karaulov, Mariana Lysenko, Daria Fomina","doi":"10.36691/rja16521","DOIUrl":"https://doi.org/10.36691/rja16521","url":null,"abstract":"Patients with PID represent a vulnerable group to the SARS-CoV2 virus with a high risk of not only severe, but also a protracted and undulating course of infection, what must be taken into account for the correct interpretation of the patient's condition and the timely administration of the appropriate therapy.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":" 45","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141128331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacogenetics of psoriasis: predictors of the efficacy of anticytokine biological therapy","authors":"Eugenia A. Shatokhina","doi":"10.36691/rja16929","DOIUrl":"https://doi.org/10.36691/rja16929","url":null,"abstract":"Although there are numerous and effective biologics therapy used for the treatment of psoriasis, primary and secondary \"non-responders\" are becoming increasingly common, and not all patients achieve remission in the long term, which has a negative impact on quality of life. Identification of genetic markers associated with response to therapy using pharmacogenetic studies is a high current issue, as this presents new opportunities for personalized medicine and will identify genetic markers for each drug group.The purpose of this review is to examine and analyze the available pharmacogenetic studies that have identified genes and their polymorphisms associated with response to biologics therapy.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"172 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140746492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical-anamnestic analysis of patients diagnosed as \"Anaphylaxis\" hospitalized in Moscow medical hospitals","authors":"Ekaterina Nikitina, M. Lebedkina, O. A. Mukhina, S. S. Andreev, A. Chernov, Nikita S Chikunov, Yulia M Klimanova, Snezhana М. Porfireva, M. A. Lysenko, D. Fomina","doi":"10.36691/rja16909","DOIUrl":"https://doi.org/10.36691/rja16909","url":null,"abstract":"Background: Anaphylaxis is a severe hypersensitivity reaction. The incidence of anaphylaxis remains underestimated and there remains a low level of vigilance among all specialties, leading to underdiagnosis and consequent lack of appropriate treatment. This work is the first systematized clinical and epidemiological study performed on a cohort of patients with a history of anaphylactic reactions (AR) over 18 years of age. \u0000Aims: study of epidemiologic features of anaphylaxis within one region of the Russian Federation, identification of its most frequent phenotypes and possible cofactors of its development, as well as analysis of the main errors in the management of patients with AR \u0000Materials and Methods: The study was conducted based on the retrospective stage analysis of data from medical records of patients with AR of the Unified Medical Information and Analytical System (EMIAS) of Moscow for the period from 2019 to 2022. The final sample comprised a cohort of 241 patients. \u0000Results: In the analyzed cohort, females (n=150; 62.2%) were predominant compared to males (n=91; 37.8%).   Medications (n-171 (70.95%) dominated the list of causative agents. The leading clinical phenotype of AR in the analyzed hospitalized cohort was characterized by cardiovascular symptoms (73 (30.3 %%)). The risks of severe course increased with age (older than 44 years) (p=0.006). At the prehospital, epinephrine therapy was given to 128 (69.9) patients out of 183 (75.9 %) patients. There was a correlation between the absence of epinephrine administration at the prehospital and the development of biphasic course of AR in the aftermath, (p0.001). Only 15 (38.5%) patients with anamnesis of anaphylaxis were previously informed about the necessity to carry epinephrine solution. It was shown that COVID-19 significantly contributed to the development of severe forms of AR (p=0.008). Conclusions: Anaphylaxis is a life-threatening pathology requiring emergency medical care, regardless of the severity of the initial symptoms. Variations in the clinical symptoms that constitute the diagnostic criteria for anaphylaxis, differences in algorithms, and limitations of existing coding systems make it difficult to summarize epidemiological data and compare study results. Older age remains a risk factor for the development of severe AnR confirmed in our cohort.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"387 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140780844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical efficacy of modern emollients in atopic dermatitis: case reports","authors":"Eugeniy V. Smolnikov, A. Litovkina, O. Elisyutina, E. Fedenko","doi":"10.36691/rja16938","DOIUrl":"https://doi.org/10.36691/rja16938","url":null,"abstract":"Atopic dermatitis (AD) is the most common chronic inflammatory skin disease, characterized by itching, chronic recurrent course, and in most cases is associated with respiratory allergies – allergic rhinitis and asthma. The incidence of AD varies from 15 to 30% or more among children and from 2 to 14% among adults in different countries. The pathophysiological mechanisms of AD are based on a genetic predisposition to allergies, immune dysregulation, and the influence of environmental factors. Recent studies have shown that a key feature of AD is a barrier defects in compromised skin which leads to increased permeability and penetration of environmental factors (e.g., microbes, allergens) and finally to allergen sensitization and to the development of specific allergic inflammation in the target organ – the skin. \u0000The article presents a series of clinical cases of moderate and severe AD, demonstrated an integrated approach to the treatment and selection of emollients, considering the phenotypic features of AD.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"317 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140778871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inborn errors of immunity: features of epidemiology and continuity of medical care in the Republic of Tatarstan","authors":"O. Skorokhodkina, A. V. Luntsov, Farida I Sibgatullina, Ekaterina O Ivanova, R. Khakimova","doi":"10.36691/rja16924","DOIUrl":"https://doi.org/10.36691/rja16924","url":null,"abstract":"Rationale: Inborn errors of the immune system represent the field of modern medicine, in particular clinical immunology, which demonstrates a high rate of accumulation of new data on this problem, which is realized in the current change in ideas about the prevalence of these diseases, revision of classification, and introduction of new treatment methods. Accordingly, many classical paradigms regarding primary immunodeficiencies (PID) have now been revised: taking into account more effective and early diagnosis, as well as modern treatment options, the prognosis of patient survival has largely changed in a positive direction, and the traditional idea of ​​the predominance of patients with early PID childhood is no longer relevant. \u0000Objective: to assess the effectiveness and level of continuity of medical care in the Republic of Tatarstan based on an epidemiological analysis of a group of patients diagnosed with PID. \u0000Methods: analysis of the register of patients living in the Republic of Tatarstan with an established diagnosis of PID, observed from 1994 to 2023. A total of 240 patients were included in the study. \u0000Results: An epidemiological analysis of primary immunity errors in the Republic of Tatarstan (RT) revealed a prevalence of 6.0 per 100,000 population, with a high proportion of patients over 18 years of age (53%), with the largest group of patients having defects in antibody production (42 %). \u0000Conclusions: the increasing relevance of the problem of PID requires special attention to the organization of medical care for patients with PID, increasing continuity between specialized pediatric services and the adult network, as well as developing issues of interdisciplinary interaction","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"184 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140762156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"POTENTIAL OF THE DOMESTIC BIOSIMILE OMALIZUMAB IN ACHIEVEMENT OF CONTROL IN PATIENTS WITH SEVERE ASTHMA.","authors":"D. Kulichenko, K. Pavlova, O. Kurbacheva, N. Ilina","doi":"10.36691/rja16916","DOIUrl":"https://doi.org/10.36691/rja16916","url":null,"abstract":"Background. Severe atopic asthma is a medical and social problem due to its prevalence, the tendency to exacerbations, the impact on the quality of life and on the work ability, and high treatment costs. The appearance biosimilar omalizumab among biologicals makes such therapy more accessible to patients. This article presents the results of an open prospective clinical study of the biosimilar omalizumab - Genolar® in patients with the severe atopic asthma. \u0000Aims: To evaluate the efficacy and tolerability of the domestically produced biosimilar omalizumab in the real clinical practice. \u0000Materials and methods. The study involved 15 adult patients (19-66 years) with a reliable history consistent with moderate to severe atopic asthma who hadn`t have asthma control at the time of inclusion in the study. All patients received the Genolar® (omalizumab, Generic JSC, Russia) for 52 weeks at the dose calculated according to the instructions. The efficacy was evaluated taking into account changes in symptom severity, improved asthma control using the Asthma Control Questionnaire (ACQ-5), pulmonary function tests, peak flow measurements, assessment the asthma exacerbations number and the healthcare resources use. \u0000Results. According to our study results, all patients demonstrated a decrease in the night and daytime attacks frequency and the shortness of breath severity due to omalizumab, which made it possible to reduce the basic therapy and refuse systemic glucocorticosteroids using in patients who previously received their. After 6 months we obtained an improvement in the asthma symptoms control (Δ ACQ-5=(-1.87), p=0.0002 compared to baseline with a trend towards further improvement in indicators and reached Δ ACQ-5=(-2.18), p=0.0001 to the 52nd week). We also obtained a statistically significant improvement in pulmonary function (after a year of treatment, the increase in forced expiratory volume in the first second was +19.85% compared to baseline, p=0.0001). No asthma exacerbation was registered during 12 months omalizumab treatment. \u0000Conclusions. Our study showed that the biosimilar Genolar® treatment in patients with severe atopic asthma allowed to achieve asthma control, decrease the exacerbations number and reduce the basic therapy volume, including oral-corticosteroid elimination.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"79 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140794217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of the sensitization spectrum in patients with severe allergic diseases using the ImmunoCAP ISAC method","authors":"M. Lebedkina, D. Fomina, Ekaterina Nikitina, A. Dushkin, A. Chernov, Y. Yukhnovskaya, M. A. Lysenko, A. Karaulov","doi":"10.36691/rja15994","DOIUrl":"https://doi.org/10.36691/rja15994","url":null,"abstract":"BACKGROUND: An important advance in modern allergology has been made by the introduction of allergenic molecules/components, including their detection by the ImmunoCAP ISAC method. This method is useful in patients with a complex spectrum of sensitization and severe forms of allergic diseases, where various predictors of severe course are actively searched for. \u0000AIMS: To evaluate the informativeness of component resolved diagnostic by ISAC ImmunoCAP method in patients with severe bronchial asthma (SBA) and severe atopic dermatitis (SAD \u0000MATERIALS AND METHODS: A single-center retrospective study was conducted from January to August 2023. 100 patients who were candidates for biologicals for SBA (63 patients) - group 1, SAD (20 patients) - group 2, or their combination (17 patients) - group 3 were included. Component restlved diagnostic was performed by ImmunoCAP ISAC method. Mathematical and statistical data processing was performed using Python3.10 programming language packages in IDE Visual Studio Code 1.76.1 (Universal). The following criteria were used: Student's, Gaims-Howell, Kraskell-Wallis, Dunn with Holm's correction. \u0000RESULTS: Polysensitization and high occurrence of food and fungal allergens were more frequently detected in","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"202 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140775958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The experience with subcutaneous allergen-specific immunotherapy with pollen allergens in patients with atopic dermatitis.","authors":"O. Elisyutina, A. Litovkina, Eugeniy V. Smolnikov, E. Fedenko","doi":"10.36691/rja16911","DOIUrl":"https://doi.org/10.36691/rja16911","url":null,"abstract":"BACKGROUND: \u0000AIMS: determination of the clinical significance of sensitization to pollen allergens in AD, determination of indications for ASIT with pollen allergens and assessment of the effectiveness and safety of this method in AD patients. \u0000MATERIALS AND METHODS: A comparative controlled study to evaluate the efficacy of SCIT with birch pollen allergens or grass in 78 AD patients were conducted. A single course of SCIT with tree pollen allergens was administered to 33 patients, and grass pollen allergens were administered to 21 patients with AD. The comparison group – AD patients on standard therapy – 24 patients. The primary endpoints were based on the reduction in the severity of AD symptoms, based on the absolute and relative number of patients who achieved SCORAD score by 75% and IGA 1/0. \u0000RESULTS: In patients received SCIT with tree pollen allergens, SCORAD 50 achieved 26%, 33%, 47% and SCORAD 75 achieved 10%, 20% and 33% after 16, 32 and 52 weeks, respectively. In patients received SCIT with grass pollen allergens, SCORAD 50 reached 31%, 40%, 58% and SCORAD 75 - 14%, 28% and 43% after 16, 32 and 52 weeks, respectively. In the comparison group: SCORAD 50 reached 24%, 32%, 37% and SCORAD 75 - 13%, 22% and 26% after 16, 32 and 52 weeks, respectively. Similar results were obtained when studying the IGA. In all study groups, an improvement of the DIQI index by 4 or more points in 12%, 25% and 37% of patients receiving one course of scASIT with tree pollen allergens, in 14%, 28% and 43% in patients after 16, 32 and 52 weeks, respectively. However, the number of such patients in the comparison group was significantly lower: 13%, 22% and 26%, respectively. \u0000CONCLUSIONS: ASIT is an effective way to treat AD patients, provided there is proven sensitization to pollen allergens","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"48 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140366664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ANALYSIS OF PATIENTS WITH COLD URTICARIA IN THE CONTEXT OF TYPICAL AND ATYPICAL FORMS.","authors":"M. Lebedkina, G. Andrenova, A. Chernov, A. Dushkin, Ekaterina Nikitina, A. Karaulov, M. A. Lysenko, D. Fomina","doi":"10.36691/rja16910","DOIUrl":"https://doi.org/10.36691/rja16910","url":null,"abstract":"BACKGROUND: Cold urticaria (ColdU) is characterized by hives and/or angioedema and/or systemic reactions in response to a cold stimulus. Typical (tColdU) and atypical forms (aColdU) have distinguished features. Currently there is limited data in the literature on patients with isolated ColdU, as well as with typical and atypical forms. \u0000 \u0000 \u0000AIMS: To analyze a cohort of patients with isolated ColdU and the characteristics of patients with tColdU and aColdU. \u0000 \u0000 \u0000MATERIALS AND METHODS: \u0000 \u0000 \u0000We conducted a single-center prospective study of 89 patients with a verified diagnosis of ColdU, who underwent provocative testing (ice cube, TempTest). In case of a positive result, tColdU was diagnosed (n=38), negative - aColdU (n=51). The tColdU group was divided into 2 subgroups - low threshold (17 degrees or less), high threshold (above 17 degrees). Correlations between characteristics in the subgroups were analyzed. Mathematical and statistical processing of the data was performed using the SPSS software package (version 22). Kraskell-Wallis and Dunn's criteria were used. For quantitative and categorical variables, dependence was assessed using Spearman correlation. \u0000 \u0000 \u0000RESULTS: \u0000 \u0000 \u0000The predominance of female gender, young age of disease onset, high prevalence of angioedema, high incidence of cold anaphylaxis (ColdA), and atopy are noted in patients with ColdU. Most patients are on therapy with standard doses of antihistamines. Patients with aColdU were younger (p=0.012), had earlier ColdU onset (p=0.003), lower basophil (p0.001) and higher eosinophil counts (p=0.007). In the high temperature group, aColdU was found to correlate with bronchial asthma (r=0.69, p0.001) and the need to escalate the dose of antihistamines (r=0.4, p=0.03). It was also revealed that patients with ColdA had lower scores on the Urticaria Control Test (UCT) questionnaire (r=-0.46, p=0.03). At the same time, higher scores correlated in this group with the duration of the disease (r=0.66, p=0.001).In the low temperature threshold group, threshold correlates with female gender (r=-0.68, p=0.003), autoimmune diseases (r=0.51, p=0.043). ColdA correlates with angioedema (r=0.65,p=0.006) and autoimmune diseases (r=0.75, p=0.001). \u0000 \u0000 \u0000CONCLUSIONS: ColdA is a significant problem, especially in countries with cold climates. There are a number of factors that distinguish tColdU from aColdU. Further research on ColdU is needed.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"50 24","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140365437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Urticaria","authors":"I. Danilycheva","doi":"10.36691/rja16934","DOIUrl":"https://doi.org/10.36691/rja16934","url":null,"abstract":"The relevance of the disease is due to its prevalence - for acute urticaria up to 20% with predominance in the paediatric population, for chronic spontaneous urticaria (CSU) up to 0.5-5% of the population. The course of the disease is characterised by unpredictability of prognosis of duration, effectiveness of standard therapy, serious impact on the quality of life of the patient, his relatives, the burden on health authorities. The lack of accurate understanding of the mechanisms of disease development, a wide range of pathogenetic treatment complicates the possibility of rapid achievement of drug remission. The clinical \u0000Recommendations contain up-to-date information on epidemiology, pathogenesis, \u0000clinical picture, differential diagnosis, possibilities of examination and stage treatment, including immunobiological therapy. The procedure of medical care, prophylaxis and dispensary observation, criteria for assessing the quality of patient management and supporting material, including questionnaires to assess the severity of the condition and the effectiveness of treatment are outlined. Clinical recommendations on urticaria are intended for practicing physicians of all specialities, students, teachers of medical schools, residents, postgraduates and researchers.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":" 960","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140382499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}